ARS Pharma Q2 FY26 net loss widens to $62.34 million; revenue rises 114.11% to $33.66 million - SPRY News | RalliesARS Pharma Q2 FY26 net loss widens to $62.34 million; revenue rises 114.11% to $33.66 million
S
SPRY• Q2 FY26 results
- ARS Pharmaceuticals posted Q2 2026 revenue of USD 33.7 million, up 114.15% from a year earlier, driven by neffy net product revenue.
- Net loss widened to USD 62.3 million, or USD 0.63 per share, versus a year-earlier loss of USD 44.9 million.
- neffy net product revenue rose to USD 26.2 million, while total U.S. epinephrine market share for Type 1 allergies doubled to 5%.
- Field-targeted account share climbed 4 percentage points to 8%, with more than 16,000 unique prescribers in the quarter.
Outlook and expenses
- Second-half SG&A and R&D expenses are guided at USD 114 million–USD 126 million; cash flow breakeven is targeted by end-2027.
HIT
•
